Meet the 10 Market Stars Behind Millionaire-Making in 2025

4. Celcuity Inc. (NASDAQ:CELC)

Celcuity climbed by 661.96 percent in 2025, with the overall rally primarily fueled by strong results from the phase 3 clinical trial of its treatment candidate for breast cancer.

In an updated report which was presented to the 2025 San Antonio Breast Cancer Symposium early last month, Celcuity Inc. (NASDAQ:CELC) said that its treatment candidate, gedatolisib, in combination with palbociclib and fulvestrant, saw patients’ cancer stay under control for around 12.4 months, while those who took the gedatolisib and fulvestrant combination saw progression-free survival (PFS) for 10 months.

The results represented a significant improvement from only 1.9 months in PFS for those who took the fulvestrant alone.

Additional safety analyses were also performed, with mouth sore the only most common side effect observed.

“We are very excited that patients reported nearly two years of delay in definitive deterioration of their well-being. This provides meaningful evidence of how well patients tolerated the gedatolisib regimens. This safety-profile, combined with the 16.6 months of median PFS reported for patients from the U.S., Canada, Western Europe, and Asia Pacific who received the gedatolisib triplet, further highlights the differentiated profile of the gedatolisib regimens,” said Celcuity Inc. (NASDAQ:CELC) Chief Medical Officer Igor Gorbatchevsky.